Format

Send to

Choose Destination
Drug Discov Today. 2017 Apr;22(4):736-743. doi: 10.1016/j.drudis.2016.12.005. Epub 2016 Dec 14.

Recombinant alpha-1-microglobulin: a potential treatment for preeclampsia.

Author information

1
Department of Medical Affairs, A1M Pharma, Lund, Sweden. Electronic address: rg@a1m.se.
2
Lund University, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.
3
Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Obstetrics and Gynecology, Lund University, Lund, Sweden.
4
Lund University, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden; Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden.

Abstract

Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia.

PMID:
27988357
DOI:
10.1016/j.drudis.2016.12.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center